Status In progress
Process STA pre-2018
ID number 1173

Provisional Schedule

Expected publication 13 March 2019

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Allergan (docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (confidentiality agreement not signed, not participating)
  Celgene (paclitaxel) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (docetaxel) (confidentiality agreement not signed, not participating)
  Eli Lilly (gemcitabine, pemetrexed) (confidentiality agreement not signed, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Peckforton Pharmaceuticals (paclitaxel) (confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (not participating)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel) (confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (docetaxel, pemetrexed) (confidentiality agreement not signed, not participating)
  Sun Pharma (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Teva UK (docetaxel) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
09 May 2018 Invitation to participate
05 April 2018 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer. The appraisal is now anticipated to begin in early May 2018 with submissions anticipated early July 2018.
21 July 2017 This appraisal will be rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
05 December 2016 Referral
05 December 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance